unravel.healthCrawled Oct 21, 2026
The device measures multiple hormones in saliva in near real time, detecting patterns blood tests cannot identify.
Unravel Health secures €2.96 million in funding to develop a portable device for at-home hormone level monitoring. Investors including Conduit EIS Impact Fund, Wrightwood, and Leo Capital support the London-based startup’s mission to empower women with self-tracking tools. The company plans to expand its product development with the new capital.
Oct 2026 · Women's TabloidNews article
Unravel Health secures €2.96 million in funding to advance its at-home saliva-based hormone testing device, which delivers results in minutes. The startup focuses on measuring multiple hormones through a simple, user-friendly sample collection method. This funding supports further development of its diagnostic technology for broader consumer and clinical applications.
Oct 2026 · FemTech WorldNews article
Unravel Health secures £2.5 million in pre-seed funding to advance its saliva-based hormone testing technology, the Micro Lab. The round is co-led by Conduit EIS Impact Fund and Wrightwood, aiming to support development ahead of planned commercial devices in 2027. The funding will help validate the platform’s accuracy and scalability for at-home diagnostics.
Oct 2026 · SesamersNews article
Unravel Health develops at-home hormone monitoring solutions to address gaps in women’s health diagnostics. Current testing methods often rely on single measurements, which fail to capture hormonal fluctuations over time—particularly for conditions like perimenopause. The company’s approach enables continuous, longitudinal tracking of hormone levels in a home setting, improving early detection and personalized care.
Oct 2026 · leo.capitalNews article
